Amgen v. Apotex

Random entry RSS

Posted in:
Legal

The Federal Circuit Affirms: The Apotex Filgrastim (Neupogen®) and Pegfilgrastim (Neulasta®) Litigation
By Daniel McCallum November 20, 2017 Comments are off
Several of the Federal Circuit’s initial decisions involving the Biologics Price Competition and Innovation Act (the “BPCIA”) focused...

Read more

Tagged with: Amgen, Amgen v. Apotex, Apotex, BPCIA, District Court, Federal Circuit, Legal, Litigation, Patent Dance

http://twitter.com/share?text="[TITLE]&url=[PERMALINK]
ShareEmail, Linked In, Twitter, Facebook, Google Plus
Posted in:
Legal

Litigation Spotlight: The Apotex Filgrastim (Neupogen®) and Pegfilgrastim (Neulasta®) Litigation
By Rachel M. Echols May 10, 2017 Comments are off
Introduction and Background The Apotex filgrastim/pegfilgrastim biosimilar litigation was the first biosimilar litigation where the...

Read more

Tagged with: Amgen, Amgen v. Apotex, Apotex, BPCIA, District Court, Featured, Federal Circuit, filgrastim, Legal, Litigation, Litigation Spotlight, Neulasta®, Neupogen®, Notice, Notice Requirement, Patent Dance, pegfilgrastim

http://twitter.com/share?text="[TITLE]&url=[PERMALINK]
ShareEmail, Linked In, Twitter, Facebook, Google Plus

Back to Top